Clinical investigation revealed that side effects associated with tamoxifen was not observed in Fulvestrant either in monotherapy or in combination with other agents, for the treatment of ER-positive advanced breast cancer [17, 18]. This evidence concerns the gene ESR1 and breast carcinoma.